Inovio Pharmaceuticals

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative

Blue Bell, US
Size (employees)
157 (est)
Inovio Pharmaceuticals is headquartered in Blue Bell, US

Key People at Inovio Pharmaceuticals

J. Joseph Kim

J. Joseph Kim


Inovio Pharmaceuticals Office Locations

Inovio Pharmaceuticals has an office in Blue Bell
Blue Bell, US (HQ)
1787 Sentry Parkway West

Inovio Pharmaceuticals Data and Metrics

Inovio Pharmaceuticals Financial Metrics

Inovio Pharmaceuticals's revenue was reported to be $10.4 m in Q1, 2017

Revenue (Q1, 2017)

10.4 m

EBIT (Q1, 2017)

(21.9 m)

Market capitalization (19-Sep-2017)

457.7 m

Cash (31-Mar-2017)

22.9 m
Inovio Pharmaceuticals's current market capitalization is $457.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


13.5 m10.5 m40.6 m8.5 m

Revenue growth, %



(19.5 m)(39.5 m)(34.3 m)(22.4 m)

EBIT margin, %

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


3.8 m1.8 m5.2 m5.3 m24.2 m8.1 m6.2 m12.5 m10.4 m

R&D expense

9.6 m7 m9.4 m16.7 m16.1 m18.2 m19.6 m27 m24.5 m

General and administrative expense

4.3 m3.2 m4.1 m4.7 m4.4 m5.4 m5.8 m5.8 m7.8 m

Operating expense total

14 m10.2 m13.5 m21.4 m20.5 m23.6 m25.4 m32.7 m32.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


33.7 m40.5 m57.6 m19.1 m

Accounts Receivable

3.3 m2.8 m7.3 m15.8 m


637.4 k798 k917.3 k1.7 m

Current Assets

58.7 m98.9 m171.9 m124.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


88.5 m70.7 m26.1 m70.3 m85.5 m41.6 m28.5 m23.3 m22.9 m

Accounts Receivable

2.9 m1.6 m3.3 m5.6 m11 m11.2 m10.4 m17.5 m9.9 m

Current Assets

112.9 m104.6 m87.3 m162.1 m184.1 m160.6 m148 m140.2 m106.8 m


10.1 m10.1 m10.1 m10.1 m10.1 m10.1 m10.5 m10.5 m10.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(66.1 m)(36.1 m)(29.1 m)(73.7 m)

Depreciation and Amortization

2.1 m1.6 m1.9 m3.1 m

Accounts Receivable

(2.5 m)499.2 k(4.5 m)(8.5 m)


(229.7 k)(160.5 k)(119.3 k)(831.8 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.7 m)(7.2 m)(10.6 m)(6.2 m)5.6 m(8 m)(18.7 m)(20.8 m)

Accounts Receivable

2.9 m1.6 m3.3 m5.6 m11 m11.2 m10.4 m17.5 m9.9 m

Accounts Payable

5.3 m4.7 m4.4 m6.1 m10.5 m12.1 m12.7 m16.2 m14.5 m
USDY, 2017


66.1 k

Financial Leverage

1.4 x
Show all financial metrics

Inovio Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

Show all operating metrics

Inovio Pharmaceuticals Market Value History

Traffic Overview of Inovio Pharmaceuticals

Inovio Pharmaceuticals Online and Social Media Presence

Inovio Pharmaceuticals News and Updates

Drugmakers Are Racing to Develop a Zika Vaccine

And not just because there's huge demand.

Zika vaccines are on a fast-track, but it won’t be fast enough to handle the current outbreak

If it seems like every time an infectious diseases reaches US soil, there’s a mad scramble to develop a vaccine—and an attending public outcry about…

The Government Just Launched Its First Zika Vaccine Trial in Humans

Days after the first U.S. Zika travel warning.

U.S. health researchers test Zika vaccine as funds run low

WASHINGTON (Reuters) - U.S. government researchers said on Wednesday they have begun their first clinical trial of a Zika vaccine while the Obama administration told lawmakers funds to fight the virus would run out in the coming weeks due to congressional inaction.

Your federal government drives innovation by investing in moonshots

 Imagine a future where “moonshots” are part of our everyday reality. Imagine that funding for these innovations comes not from Silicon Valley venture capital, eccentric billionaires or maverick corporations, but instead from the United States government, which has already invested in moonshot techn…

CORRECTED-Zika vaccines prove 100 percent protective in mice; monkey study shows promise

CHICAGO, June 28 (Reuters) - Mice given a single shot of one of two experimental Zika vaccines were completely protected when exposed to the virus one to two months later, a promising sign that similar vaccines under development for humans will protect against Zika, U.S. researchers said on Tuesday.…
Show more

Inovio Pharmaceuticals Company Life and Culture

You may also be interested in